Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.58 |
| ▸ | CTSK | P43235 | 5/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 4/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10135746 | 0.90 | CTSS (0.70) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL22962299 | 0.90 | CTSS (0.70) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL10135530 | 0.88 | CTSS (0.60) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL14190232 | 0.86 | CTSS (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL12203694 | 0.85 | NPC1 (0.63) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL3676162 | 0.85 | NPC1 (0.63) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL29401299 | 0.85 | NPC1 (0.63) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL3676166 | 0.85 | NPC1 (0.63) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL8351065 | 0.84 | CTSS (0.56) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL8351950 | 0.84 | CTSS (0.56) | CTSSCTSKCTSBCTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644019-B2 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | SHIRE LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-7678770-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | CTSS 1737/4885CTSK 1897/4885CTSB 675/4885 |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | CTSS 1737/4885CTSK 1897/4885CTSB 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.